Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GenVec
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Head and neck cancer
Patients must have a locoregional tumor amenable to reirradiation with curative intent.
disease, or the majority of disease, should be accessible to injection via direct intratumoral injection
Life expectancy of greater than 12 weeks
Age \> 18 years
ECOG performance status 0-1
You may not be if
Metastatic disease
History of malignancy (other than head and neck cancer) in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient
Patients may not be receiving any other investigational agents currently or within the 4 weeks prior to study Day 1
Active infection of any type
Chronic treatment for greater than 6 months with steroids
Pregnant or lactating women
Patients with known history of cerebral vascular disease; stroke or TIA within the last 6 months
Patients with history of documented thrombosis (PE or DVT), or known coagulopathy or thrombophilia, or evidence of DVT / thromboembolic event upon enrollment
Patients receiving hormone replacement therapy or hormonal contraceptives within two weeks of day 1
Patients who have undergone surgery within the last 1 month prior to day 1
Patients with active carotid artery involvement or status post carotid artery graft / stenting
Clareo Health | A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
